Advancements in Biotech with Spiro Rombotis

In this episode, host Shikha Jain, MD, speaks with Cyclacel CEO, Spiro Rombotis, MPH, about developing techniques and therapies for drug development, how technology has affected these advancements and more. •    Welcome to another exciting episode of Oncology Overdrive 1:15 •    About Rombotis 1:23 •    The interview 2:21     •    Can you tell us about how you ended up in the biotech and pharma spaces?  2:41 •    How did you transition to the first CEO of Cyclacel, and what has kept you in the same space for over three decades?  4:45 •    Is this how you envisioned your career? How did this vision evolve over the course of your career?  8:53 •    What does Cyclacel do, and can you describe the types of innovation you are doing there? 10:19 •    With all this new and exciting technology in the field, where do you see epigenetics and precision oncology going in the next ten to twenty years?  15:46 •    What are your thoughts on AI in the oncology space?   22:21 •    Jain and Rombotis on checks and balances when it comes to AI use in cancer care and clinical trials.   27:53 •    What’s next for you?  30:53 •    If someone could only listen to the last few minutes of this episode, what would you want them to take away? 36:18 •    How to contact Rombotis 40:25 •    Thanks for listening 40:43 Spiro Rombotis, MPH, is the CEO of Cyclacel. He has over 36 years at three public biotechs and two pharmas.

We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Rombotis can be reached via email [email protected].  Disclosures: Jain reports no relevant financial disclosures. Rombotis reports Cyclacel Ltd employment and stock ownership.